Agile Therapeutics, Inc. (NASDAQ:AGRX) insider Renee Selman bought 7,250 shares of the firm’s stock in a transaction dated Friday, August 25th. The shares were acquired at an average price of $3.35 per share, for a total transaction of $24,287.50. Following the completion of the transaction, the insider now directly owns 60,583 shares in the company, valued at approximately $202,953.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Agile Therapeutics, Inc. (NASDAQ AGRX) opened at 3.26 on Tuesday. Agile Therapeutics, Inc. has a 12 month low of $1.82 and a 12 month high of $7.95. The stock’s 50 day moving average is $3.95 and its 200 day moving average is $3.33. The stock’s market capitalization is $93.91 million.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. During the same quarter last year, the firm earned ($0.29) EPS. Analysts anticipate that Agile Therapeutics, Inc. will post ($1.03) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/agile-therapeutics-inc-agrx-insider-renee-selman-acquires-7250-shares-of-stock/1529109.html.

Large investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. boosted its stake in Agile Therapeutics by 39.2% in the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after buying an additional 780,578 shares in the last quarter. Royce & Associates LP boosted its stake in Agile Therapeutics by 206.1% in the first quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock valued at $3,165,000 after buying an additional 665,000 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in Agile Therapeutics during the second quarter valued at about $309,000. Dimensional Fund Advisors LP boosted its stake in Agile Therapeutics by 604.2% in the second quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after buying an additional 82,213 shares in the last quarter. Finally, LMR Partners LLP purchased a new stake in Agile Therapeutics during the second quarter valued at about $211,000. 67.59% of the stock is currently owned by institutional investors.

AGRX has been the topic of several recent research reports. Cantor Fitzgerald restated a “buy” rating and set a $9.00 target price on shares of Agile Therapeutics in a research report on Monday, May 8th. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a research report on Wednesday, June 14th. Janney Montgomery Scott restated a “buy” rating and set a $13.00 target price (down from $15.00) on shares of Agile Therapeutics in a research report on Thursday, August 24th. HC Wainwright initiated coverage on shares of Agile Therapeutics in a research report on Wednesday, July 19th. They set a “buy” rating and a $10.00 target price on the stock. Finally, Royal Bank Of Canada set a $8.00 target price on shares of Agile Therapeutics and gave the company a “buy” rating in a research report on Sunday, July 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Agile Therapeutics has an average rating of “Buy” and an average target price of $8.75.

About Agile Therapeutics

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.